Inhaled corticosteroids and increased microbial load in COPD: potential role of epithelial adhesion molecules
نویسندگان
چکیده
منابع مشابه
Inhaled corticosteroids in COPD
C hronic obstructive pulmonary disease (COPD) is arguably the most common chronic disease of the lungs at present and, by 2020, it will be the third leading cause of death worldwide. COPD is associated with a relentless decline in forced expiratory volume in 1 second (FEV1) and, in the later stages, the condition progresses to pulmonary hypertension and hypoxic respiratory failure. Few interven...
متن کاملInhaled corticosteroids in COPD
The importance of presenting absolute cell numbers when counting cells in biological samples is illustrated by the potentially misleading interpretation of data in the paper by Marco Confalonieri and colleagues. The authors concluded that, in addition to reduced sputum neutrophilia, the number of sputum macrophages increased significantly following treatment with inhaled beclomethasone dipropio...
متن کاملInhaled corticosteroids and mortality in COPD.
STUDY OBJECTIVES To assess the influence of inhaled corticosteroids (ICSs) on mortality in COPD patients, which is currently a controversial topic. SETTING Manitoba Health maintains a population-wide research database that includes pharmaceutical information. DESIGN AND PATIENTS We examined mortality in people 90 to 365 days after hospital discharge for COPD, comparing those persons who rec...
متن کاملInhaled Corticosteroids in COPD: A Controversy
Inhaled corticosteroids (ICS) are now very widely used in high doses in the management of COPD patients. In sharp contrast to the situation in asthma, ICS provide little or no benefit in COPD patients and may have long-term detrimental effects. High doses of ICS fail to reduce disease progression or mortality, even when combined with a long-acting 2 -agonist (LABA). Several trials have demonstr...
متن کاملInhaled corticosteroids in COPD: a controversy.
Inhaled corticosteroids (ICS) are now very widely used in high doses in the management of COPD patients. In sharp contrast to the situation in asthma, ICS provide little or no benefit in COPD patients and may have long-term detrimental effects. High doses of ICS fail to reduce disease progression or mortality, even when combined with a long-acting beta(2)-agonist (LABA). Several trials have dem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2018
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.02257-2017